

10/518360

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
WO 03/105728 A1

(51) International Patent Classification<sup>7</sup>: A61F 2/06, 2/02

(21) International Application Number: PCT/EP03/50231

(22) International Filing Date: 17 June 2003 (17.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02100720.8 18 June 2002 (18.06.2002) EP

(71) Applicant (for all designated States except US): F.R.I.D. R & D BENELUX SPRL [BE/BE]; Rue Descartes 2, B-7000 Mons (BE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FRID, Nouredine [BE/BE]; Kerkveldstraat 190, B-1650 Beersel (BE).

(74) Agents: Van Straaten, Joop et al.; OFFICE KIRKPATRICK, Avenue Wolfers, 32, B-1310 La Hulpe (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEMODYNAMIC LUMINAL ENDOPROSTHESIS



(57) Abstract: A multilayer braided luminal self-expanding stent (4) for an anatomical conduit (8) comprising a outer braided peripheral stent (10) which is permanently linked to an inner, braided, hemodynamic flow deflector (2) by at least a pair of filaments (12) that make part of a common braided structure.

WO 03/105728 A1

Hemodynamic luminal endoprosthesis

The invention concerns luminal endoprostheses to be placed in blood vessels, such as stents.

5

Background of the invention

Stents are generally placed within the lumen of a narrowed artery in cases when the outcome of angioplasty is uncertain, e.g. in the case of stenoses, recanalized occlusions or vessel dissection.

When a stent is unfolded, it applies a constant outward force on the vessel, maintaining the desired dimensions of the lumen and thus reducing the effects of stenosis.

However, recent studies on the subject revealed that placement of a luminal endoprosthesis can cause injuries to the artery wall, which leads to what is called intimal hyperplasia.

The vascular wall is composed of three layers, namely the intima (innermost layer composed of a single layer of endothelial cells), the media (middle layer which is composed of smooth muscle cells, elastic sheets, elastic fibrils network and bundles of collagenous fibers) and the adventitia (the outer layer).

It is now well established that intimal hyperplasia is the main process that induces belated narrowing of the lumen, even one or two years after intervention. It is related to the loss of endothelium and to medial injuries, which lead to an accelerated luminal smooth muscles proliferation migrating from the media or the intima and later to atherosclerosis degeneration.

Presently, studies to reduce what is called intimal hyperplasia (small muscle tissue proliferation which leads to restenosis) are aimed at anti-proliferation or anti-mitotic drugs that are fixed on the stent surface  
5 via a polymer matrix.

These methods suffer from several difficulties:

- the non uniformity of polymer surface and consequently the lack of consistency of the local drug delivery.
- the lack of consistency of the kinetic degradation of  
10 the polymer matrix.
- the stability of the polymer fixation on the surface of the stent.
- the determination of the right value of the drug dose to be affixed on the matrix.

15 The drugs used are similar to those which are used as anti-cancer drugs, e.g. Taxol and Rapamycin. The use of high amounts of these molecules could be very harmful for the patient.

The restenosis of the stent induced by intimal  
20 hyperplasia poses a major problem for stent efficiency, mainly for arteries such as femorals, internal carotids or coronaries.

For the femoral artery, for example, many clinical trials show that stents give poor results due to the  
25 restenosis which is a consequence of intimal hyperplasia; 50 to 60% failure.

A new approach showed that the restenosis was bound to unexpected mechanical problems:

30 Femoral artery:

A low shear stress along the cell wall is considered as an important factor of atherosclerotic plaque formation. It has been correlated with intimal thickening

and has been shown to alter endothelial cells structure and function.

The disturbed flow increases cell turnover particularly in the areas of low blood velocity, which could explain the loss of contact inhibition of cell growth.

#### Internal carotid:

The human carotid bifurcation is another example where flow model studies have demonstrated that the intimal plaques form in the low shear stress region of the carotid sinus opposite the flow and not in the high shear stress region along the inner wall of the carotid artery.

#### Coronary artery

Similarly, the low shear stress is now shown to be a main cause of plaques formation at the branch points just distal to the bifurcation of the left main coronary artery into LAD and circumflex. This region exhibits a low blood flow velocity and a low shear stress, in other words the coronary artery tree demonstrates also a relationship between the shear stress and plaque formation.

The coronary arteries are subject to two systolic phases and one diastolic flow episode during each cardiac cycle, thus potentially placing them at a higher risk rank than systemic arteries to atherosclerosis. Shear stress oscillation is directly influenced by heart rate. At higher rate, coronary arteries are exposed to more acute oscillatory than at low shear stress episodes, which accelerate the formation of atherosclerosis plaques. For example, an increase in the mean heart rate

from 70 to 80 beats/min would result in an increase of over 5 million heart beats per year. The duration of the systolic phase is generally constant for varying heart rates, whereas the duration of diastolic phase shortens with increasing heart rates.

It is important to mention that the effect of heart rate on atherosclerosis is associated with carotid artery atherosclerosis.

Many stents are well known and are described in the prior art.

In WO 01/01887, it is disclosed a composite stent which comprises an inner PTFE tubular structure and an outer PTFE tubular structure assembled about the inner structure and between these two structures is interposed a distensible stent. Thus, this layered structure improves both axial and radial compliance of the stent.

The invention described in WO 02/47579 concerns a prosthesis for blood vessels whose frame comprises a plurality of interconnected layers which are formed of two interwoven frame wires. This configuration allows increasing both the stability and the strength of the stent.

However there is no document in the prior art which discloses the feature of the present invention to favour blood flow.

#### Summary of the invention

A higher flow velocity could suppress neointimal hyperplasia. However, this seems at first sight an absurdity, because it implies that, at constant flow rate, the section would have to be reduced. This led to the idea to design a stent in such a way that the flow velocity would remain globally the same, but would be

increased along the cell wall, consequently improving the shear stress at wall level.

During the 12<sup>th</sup> conference of the European Society of Biomechanics (Dublin 2000) Nikos Stergiopolos demonstrated that avoiding intimal hyperplasia proliferation mainly in the case of low flow could be done by placing a streamlined cylindrical body in the centre of blood stream. The body deflects the central core of flow towards the wall, increasing the wall shear stress.

However, this brilliant theory could hardly be reduced to practice. The placing of a cylinder in the centre of the stream line of a diseased artery is not easy by itself, and it needs to be coupled with the prior placing of a standard stent, both to hold the atherosclerosis plaques and to anchor the cylinder. The inner cylinder further needs to be stable and firmly held in place.

The Applicant has developed a stent made out of a plurality of interlaced braided layers of metal filaments.

Prior experience in this field allowed him to develop a new type of stent which is braided in such a way that the making of a peripheral stent, a central deflecting cylinder and a linking between these two elements is achieved in a single shot.

The subject of the invention is a multilayer braided luminal self-expanding stent for an anatomical conduit comprising a outer braided peripheral stent which is permanently linked to an inner braided hemodynamic flow deflector by at least two filaments that make part of the common braided structure, the gap between the two commonly braided structures is broadly between 10 to 90% of the nominal diameter of the outer stent.

The multilayer technology seems to be the right solution because it is possible to have in one shot both cylinders made and simultaneously linked together.

In other words, a multilayer machine which is able to braid six layers in one shot could be used to braid the first two layers together around a mandrill with the full number of wires needed.

The second and the third layers will handle only four or eight carriers with filled wires in order to connect the first two layers to the last two ones.

The result is a self-expanding stent as described above.

The two cylindrical structures are linked together by this multilayer technique in such a way that they form one single body.

The advantage of this design is that, when put in place, it increases the velocity of the blood along the inner wall of the vessel and thereby the shear stress. An increase of shear stress of the blood elongates endothelial cells in the direction of the flow. The cells also align themselves in the direction of the flow, and the shape of a confluent layer of endothelial cells changes from polygonal to ellipsoid when exposed to unidirectional shear. Endothelial cells produce nitric oxide, which is an important element for maintaining the vasodilator or vasorelaxing tonus in blood vessels. Nitric oxide inhibits platelet aggregation and adhesion, and modulates leukocyte adhesion and migration. In other words inducing the production of nitric oxide prevents stent restenosis by eliminating intimal hyperplasia thickening.

Brief description of the figures

Other particulars and advantages of the invention will become apparent from the description hereinafter of some particular embodiments of the invention, reference being made to the appended drawings in which:

Fig. 1 is a sketch of the aspect of the blood flow, with and without the inner core of a stent according to the invention.

Fig. 2 is a sketch of a sectional view along the axis of the stent.

Fig. 3 is a sketch of a sectional view normal to the axis of the stent

Detailed description of the figures

Fig. 1 shows a diagrammatical view of the velocity profile of a flow of blood, with (right side of the Fig 1) or without (left side of the Fig 1) the hemodynamic deflecting core 2 of the stent of the invention 4.

In the absence of core 2, the velocity cube 6a is classical: the velocity decreases progressively from a maximum to zero at the very contact of the wall 8, allowing the anarchic growth of wall cells that in time will impede the even passage of blood.

Turning now to the left side of the figure, one can see that the blood, deflected from the centre of the vessel by the hemodynamic core 2, induces a steeper flow profile 6b near the wall 8. The shear stress thus improved drags along the molecules that would induce a reaction of the wall cells.

Fig. 2 and 3 display the general structure of the stent 4, that exhibits a central hollow braided hemodynamic core 2 and a "classical" peripheral stent



structure 10, the core and the peripheral structures being linked by wires 12 belonging to both braids.

To obtain this kind of structure, at least one or two wires are braided in helix simultaneously with the inner and the outer layers of braiding.

To control the empty space between the two cylindrical structures, the easiest way is to fill the intermediate spindles with filaments of a material that is able to be dissolved (e.g. in hot water) after the braiding process, thus leaving a corresponding empty space in the braiding.

Example :

A braiding machine is equipped with spindles so as to be able to realise a multilayer braid made out of 24 or 48 wires, according to the nominal size of the stent.

The spindles corresponding to the first two layers are loaded with metal wires. The spindles corresponding to the 3<sup>rd</sup> layer are loaded with PVA (polyvinylalcohol) filament (Kuralon® or Solveon®), but for two to five of them (according to the final size of the stent), that are loaded in a symmetrical way (thus in a diametrically opposed position), by metal wires. These metal wires which make the junction with the last two layers, are made out, as the first and second one, of metal.

When the braiding is finished, the braid is extracted from the mandrel on which it has been braided. It is then put in hot water (between 50 and 70°C) so as to dissolve the PVA filaments, thus freeing the space between the two distinct -inner and outer- structures.

The thickness of the PVA filament can be varied according to the width to be preserved between the peripheral stent and the inner core 2. The dimensions of

the hollow inner core 2 itself are sufficient to modify the hemodynamic conditions of the blood flow, as described above.

In vitro experiments showed that the shear stress must reach a value of  $15 \text{ dyne/cm}^2$  to affect the growth of endothelial cells. Below this value, the shear stress induce the formation of plaque and an anarchic growth of muscular cells. Below  $2 \text{ dyne/cm}^2$ , the neointimal formation increases sharply, provoking rapid lesions.

The framework of the present stent can be made out of nickel titanium alloy or in cobalt alloy as Elgiloy or Phynox, or in stainless steel.


The metal wires can be submitted to a thermal treatment so as to reach a rigidity sufficient to withstand the crushing.

A further advantage of the present structure is that it reacts as a single element, capable of being squeezed and to elongate exactly as a classical stent. The structure is also very light, it can be reduced to a minute diameter, allowing an easy placement and a very good flexibility. It is further possible to use classical applicators to put it in place in a single operation.

## CLAIMS

1.- A multilayer braided luminal self-expanding stent (4) for an anatomical conduit (8), expendable from a reduced diameter to a nominal diameter, comprising a outer braided peripheral stent (10) which is permanently linked to an inner braided hemodynamic flow deflector (2) by at least a pair of filaments (12) that make part of a common braided structure, a gap of between 10 to 90% of the nominal diameter of the outer stent (10) extending between the inner and outer parts of the commonly braided structure.

2.- A multilayer stent according to claim 1 characterised in that the outer structure (10) comprises a first and a second layer which are connected by at least a pair of filled wires (12) in order to connect the first two layers to the deflector, the latter comprising last two layers.



**Fig 1**

Fig 3





Fig 2



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/50231

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61F2/06 A61F2/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 01887 A (SCIMED LIFE SYSTEMS INC) 11 January 2001 (2001-01-11) page 6, line 15 - line 18; figures page 9, line 29 -page 10, line 5	1,2
P,Y	EP 1 234 554 A (ENDOART SA) 28 August 2002 (2002-08-28) paragraph '0012! - paragraph '0013!; figures	1,2
A	EP 1 153 581 A (ENDOART S A) 14 November 2001 (2001-11-14) claims; figures	1,2
A	US 6 348 066 B1 (DEREUME JEAN-PIERRE ET AL) 19 February 2002 (2002-02-19) claims; figures	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

22 October 2003

Date of mailing of the international search report

28/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50231

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0101887	A	11-01-2001	US 2001023370 A1 CA 2377961 A1 EP 1194080 A1 JP 2003503151 T WO 0101887 A1	20-09-2001 11-01-2001 10-04-2002 28-01-2003 11-01-2001
EP 1234554	A	28-08-2002	EP 1234554 A1 WO 02065948 A1	28-08-2002 29-08-2002
EP 1153581	A	14-11-2001	EP 1153581 A1	14-11-2001
US 6348066	B1	19-02-2002	US 5628788 A US 2002173836 A1 US 2003149472 A1 US 2001044647 A1 AU 726881 B2 AU 5633798 A CA 2229685 A1 EP 0861638 A2 JP 3051104 B2 JP 10234861 A AU 703673 B2 AU 7668996 A EP 0877581 A1 JP 11501243 T JP 3390450 B2 NO 982052 A WO 9717039 A1	13-05-1997 21-11-2002 07-08-2003 22-11-2001 23-11-2000 03-09-1998 27-08-1998 02-09-1998 12-06-2000 08-09-1998 01-04-1999 29-05-1997 18-11-1998 02-02-1999 24-03-2003 02-07-1998 15-05-1997

**THIS PAGE BLANK (USPTO)**